Speaker illustration

Doctor David Wood

Chapel Hill (United States of America)

David R. Wood is the current Head of Medical Affairs at Milestone Pharmaceuticals, a bio-pharmaceutical company developing therapeutic treatments for PSVT and other arrhythmias. He holds a PhD in Biomedical Science, focused in Molecular Genetics and Cellular Biology. His career began in an academic research setting and was related to stem-cell and gene therapy for the treatment of cardiovascular and metabolic disorders. He has since established a career track-record as an entrepreneur and medical scientist leader, experienced in academic and industry research across a broad range of therapeutic areas. He has a particular passion for education and research related to diseases of under-served populations. He operates under a leadership philosophy of serving those he leads and always with the ultimate needs of the patient in mind.

Prevalence of patients with paroxysmal supraventricular tachycardia (PSVT) in the United States

Event: ESC Congress 2019

Topic: Cardiovascular Epidemiology

Session: Cardiovascular epidemiology and trials


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb